26.02.2018
- US drugmaker Bristol-Myers Squibb has struck a deal worth $3.6 billion with biotech Nektar Therapeutics to jointly develop and commercialize the latter’s lead anticancer molecule –...
31.07.2017
- US pharma companies Eli Lilly and Nektar Therapeutics have signed an agreement to jointly develop the latter’s novel immunotherapy, NKTR-358, which could potentially treat a number...
